Team:Wageningen UR/Modeling

From 2012.igem.org

(Difference between revisions)
(Introduction)
(Modeling)
 
(123 intermediate revisions not shown)
Line 1: Line 1:
-
{{Template:Ecoil}}
+
{{Template:WUR}}
 +
<html>
 +
<script>
 +
document.getElementById("header_slider").style.backgroundImage = "url(https://static.igem.org/mediawiki/2012/d/d2/HeaderModeling.jpg)";
 +
</script>
 +
</html>
-
== Modelling ==
+
= Modeling =
-
=== Introduction ===
+
Formation of modified Virus-Like Particles is key to the success of our project. Therefore we first [[Team:Wageningen_UR/InSilico|predict the structure of the subunits]] after which we use a [[Team:Wageningen_UR/FormationModel|model describing the formation of the whole VLPs]].
-
Modelling can be the final application, which could be modelling the VLP dose in case of drug delivery. A second possibility is predicting the folding of VLPs. It is known that the modification of a monomer influences the folding of the total VLP. Looking at the loops of the Hepatitis B VLP, this makes sense. These loops would be the primary target for modification, but are paired in the VLP structure. So, if the loops of both monomers are modified, it is very likely that the modification will interfere with the VLP formation.
+
Finally, we wanted to know the applicability of our device. Therefore, we used a human body model which is based on the model made by the [[Team:Slovenia/ModelingPK|Slovenia 2012 iGEM team]]. We extensively modifyed this model to make it applicable for VLPs, their affinity with diseased tissue, the speed of excretion and degradation and finally, the drug delivery at the targeted tissue.
 +
 
 +
*[https://2012.igem.org/Team:Wageningen_UR/HumanBody Human Body Model]
 +
*[https://2012.igem.org/Team:Wageningen_UR/InSilico Tertiary Structure Modeling]
 +
*[https://2012.igem.org/Team:Wageningen_UR/FormationModel VLP Assembly Model]

Latest revision as of 19:12, 26 October 2012

Modeling

Formation of modified Virus-Like Particles is key to the success of our project. Therefore we first predict the structure of the subunits after which we use a model describing the formation of the whole VLPs.

Finally, we wanted to know the applicability of our device. Therefore, we used a human body model which is based on the model made by the Slovenia 2012 iGEM team. We extensively modifyed this model to make it applicable for VLPs, their affinity with diseased tissue, the speed of excretion and degradation and finally, the drug delivery at the targeted tissue.